Skip to main content
. Author manuscript; available in PMC: 2018 Mar 19.
Published in final edited form as: Cancer Immunol Res. 2017 Oct 15;5(11):1029–1045. doi: 10.1158/2326-6066.CIR-17-0175

Table 2.

TNFα-mediated tumor outgrowth

Viable cultures of B16 MRD
First-line therapy inducing MRD −TNFα +TNFα
B16tk/GCV 0/7 5/5
B16tk/i.t. Reovirus 1/9 4/4
B16ova/OT-I 0/7 5/7
B16tk/Pmel/VSV-hgp100 1/4 3/3
Total 2/27 (7%) 17/19 (89%)